Affinity Asset Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Affinity Asset Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,500,000	Closed	-$183M	–	120
2025 Q4	$183M	Buy	+1,500,000	New	+$172M	10.42%	1
2025 Q2	–	Sell	-500,000	Closed	-$40.5M	–	117
2025 Q1	$40.5M	Sell	500,000 -250,000	-33%	-$22.3M	3.87%	5
2024 Q4	$67.5M	Buy	+750,000	New	+$72.7M	9.05%	1
2024 Q2	–	Sell	-700,000	Closed	-$66.4M	–	124
2024 Q1	$66.4M	Buy	+700,000	New	+$65M	8.22%	1
2021 Q4	–	Sell	-700,000	Closed	-$88M	–	74
2021 Q3	$88M	Buy	700,000 +500,000	+250%	+$64.4M	22.22%	1
2021 Q2	$27.1M	Buy	+200,000	New	+$26.3M	9.69%	2

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Affinity Asset Advisors's XBI Position: Q3 2024 in Review

Affinity Asset Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2024, closing a stake of 37,550 shares — an estimated $3.48M sold.

Affinity Asset Advisors first reported a position in XBI in Q2 2024 and held it in 1 quarter. The position peaked at $3.48M in Q2 2024. 769 funds tracked by Wall St. Rank hold XBI as of Q3 2024.

Affinity Asset Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2024 after selling out during the quarter.
Affinity Asset Advisors sold 37,550 State Street SPDR S&P Biotech ETF shares in Q3 2024, an estimated $3.48M.
Affinity Asset Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2024 and held it in 1 quarter.
Affinity Asset Advisors's State Street SPDR S&P Biotech ETF position peaked at $3.48M in Q2 2024.
769 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2024.

Based on Affinity Asset Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.